Backed by OrbiMed and J&J to build precision bacteria-killing tool, BiomX adds a slate of investors in $32M Series B
When it comes to tinkering with the multitude of bacteria residing in our bodies for disease treatment, antibiotics has been the go-to for eliminating bad ones while the burgeoning crop of microbiome biotechs aim to add “good” microbes to the mix. But a Weizmann Institute spinout working out of the Kendall Square of Israel is charting a path between those two approaches with the clinical stop in sight.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.